AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01341990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel Contact Lenses
Description: Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
Study NCT01341990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Hydrogel Contact Lenses
Description: Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
Study NCT03010735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: Daily take 4.0E+10 CFU of probiotics
Study NCT03010735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00386308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 3900 mg/Day
Study NCT00386308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT04377022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Therapy (Aerobic Exercise in addition to conventional therapy)
Description: There are two intervention arm in the study~1. Combined therapy~2. Conventional Therapy
Study NCT00890643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prazosin hydrochloride
Description: prazosin 1-20 mg/day in divided doses
Study NCT00890643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00663117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone-HCl
Description: naltrexone 4.5 mg
Study NCT00663117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone-HCl
Description: naltrexone 4.5 mg
Study NCT00663117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00445601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given intravesically
Study NCT00445601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given intravesically
Study NCT00338767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Description: DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
Study NCT00338767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Medication treatment includes flouxetine for treatment of depression.
Study NCT01971320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urostim I stimulation
Description: Urostim I stimulation will be done during meals for 6 weeks
Study NCT01971320 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Urostim I stimulation
Description: Urostim I stimulation will be done during meals for 6 weeks
Study NCT01804673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-ITS
Description: Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
Study NCT03671720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: personalized DC vaccine
Description: personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
Study NCT04329143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open completion cholecystectomy
Description: open excision of cystic duct remnant
Study NCT04329143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lap completion cholecystectomy
Description: lap excision of cystic duct stone
Study NCT01177202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAC1 Vaccine
Description: Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
Study NCT04628871 — intervention group
Intervention type: BIOLOGICAL
Intervention: SB-FIX
Description: No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
Study NCT03626051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid tape
Description: This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
Study NCT03626051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibular tape
Description: This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
Study NCT01125891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
Study NCT01125891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
Study NCT01531790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
Study NCT01531790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centrum
Description: 1 tablet/day
Study NCT04265989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single BMS
Description: Single bare metal stent covered the coronary artery aneurysm
Study NCT04265989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single or Double BMS
Description: Single or double layer bare metal stents covered the coronary artery aneurysm
Study NCT04265989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single or Double BMS
Description: Treated with single or double layer bare metal stents
Study NCT04265989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMS+DES
Description: Treated with bare metal stent combined with drug eluting stent
Study NCT02742740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chemo Buddy
Description: The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
Study NCT01326962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
Study NCT01825434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019
Description: NCFM Group
Study NCT01300377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine / Lidocaine
Description: 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
Study NCT01300377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
Study NCT01065129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT01065129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study NCT01065129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT01177202 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HAC1 Vaccine
Description: Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
Study NCT01177202 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAC1 Vaccine
Description: Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
Study NCT04610424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooperative Parent Mediated Therapy (CPMT)
Description: CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
Study NCT04610424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: As usual
Description: Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
Study NCT04610424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: As usual
Description: Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
Study NCT03728153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 MG Oral Tablet
Description: Once-daily dosing for 90 days
Study NCT03386695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education by Pamphlets
Description: Distribution of pamphlets with information of prevention and early detection of cervical cancer and written as well as pictorial depiction on how to collect cervical self sample for HPV detection.
Study NCT03386695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health education programme
Description: Health education program explaining about prevention and early detection of cancer and education on method of collection of cervical self sample for HPV.
Study NCT01820468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted critical time intervention team
Study NCT00678444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
Study NCT02543723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse Coach Intervention
Description: Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
Study NCT01935960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01935960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01935960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01935960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoid 9cUAB30
Description: Given PO
Study NCT03661229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVInsight Monitoring
Description: All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
Study NCT02347449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires, Oncotype Dx Assay
Description: 1. Physician pre-assay questionnaire~2. Patient pre-assay questionnaire~3. Oncotype DX® Assay~4. Physician post- assay questionnaire~5. Patient post-assay questionnaire
Study NCT01456858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide Treated Polyethylene Sheeting
Description: Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
Study NCT01456858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Untreated Plastic Sheeting
Description: Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
Study NCT03420092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 1 of AZD5718 tablets
Description: The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
Study NCT03420092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 2 of AZD5718 tablets
Description: The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
Study NCT03420092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 3 of AZD5718 tablets
Description: The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
Study NCT03420092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 4 of AZD5718 tablets
Description: The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
Study NCT03420092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Form 5 of AZD5718 tablets
Description: The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
Study NCT03420092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selected form (Form 2 - 5) of AZD5718 tablets
Description: The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
Study NCT00009945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clodronate
Description: 1600 mg PO daily
Study NCT00009945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 pills PO daily
Study NCT03469401 — intervention group
Intervention type: OTHER
Intervention: Intervention
Description: Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
Study NCT00840840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
Description: 1 x 600 mg/42.9 mg/5 mL, single-dose fasting
Study NCT00840840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin ES-600™
Description: 1 x 600 mg/42.9 mg/5 mL, single-dose fasting
Study NCT03187821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser peripheral iridotomy
Description: location of laser peripheral iridotomy
Study NCT01859650 — intervention group
Intervention type: OTHER
Intervention: MR and CT imaging
Study NCT02151539 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Ancillary studies
Study NCT01993186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Description: oral liquid
Study NCT01993186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral liquid
Study NCT04320563 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rexon-eye
Description: This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
Study NCT04320563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rexon-eye
Description: This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
Study NCT03862547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A peripheral blood sample from the cubital vein
Description: Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species.
Study NCT02151539 — intervention group
Intervention type: OTHER
Intervention: quality-of-life assessment
Description: Ancillary studies